title: Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma.
abstract: In the WHO classification, the majority of Hodgkin-like ALCL cases as defined by the REAL classification are considered to be CHL. However, establishing a histological diagnosis for the gray zone between CHL and ALCL is often confusing. In this study, we re-evaluated such cases by performing immunohistochemistry with antibodies against PAX-5/BSAP, Oct.2, and BOB.1/OBF.1. Expression of PAX-5/BSAP was observed in 88% (76/87) of CHL specimens and none (0/11) of ALK-positive ALCL specimens. Among specimens of Hodgkin-like ALCL and ALK-negative ALCL, expression of PAX-5/BSAP was observed in 77% (20/26) and 18% (3/17), respectively. Most of the PAX-5/BSAP-positive specimens were negative for Oct.2 and/or BOB.1/OBF.1 except for four CHL specimens. Our results may support the WHO classification in which most cases of Hodgkin-like ALCL are classified as CHL. However, the patients with Hodgkin-like ALCL with CHL-immunophenotype (PAX-5/BSAP-positive and negative for Oct.2 and/or BOB.1) did not have a favorable outcome, with a 5-year OS rate of 58%.
authors.affiliation: Department of Pathology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. jtamaru@saitama-med.ac.jp
authors.forename: Jun-Ichi
authors.initials: J
authors.lastname: Tamaru
authors.forename: Michihide
authors.initials: M
authors.lastname: Tokuhira
authors.forename: Nozomi
authors.initials: N
authors.lastname: Nittsu
authors.forename: Shigeo
authors.initials: S
authors.lastname: Nakamura
authors.forename: Ryo
authors.initials: R
authors.lastname: Ichinohasama
authors.forename: Ritsuro
authors.initials: R
authors.lastname: Suzuki
authors.forename: Hiraki
authors.initials: H
authors.lastname: Mori
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Takagi
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Jun
authors.initials: J
authors.lastname: Itami
authors.forename: Shinji
authors.initials: S
authors.lastname: Itoyama
authors.forename: Atsuo
authors.initials: A
authors.lastname: Mikata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D014408:Biomarkers, Tumor / Q000235:genetics; D003937:Diagnosis, Differential; D005260:Female; D015973:Gene Expression Regulation, Leukemic; D006689:Hodgkin Disease / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D006801:Humans; D016130:Immunophenotyping; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D050813:Octamer Transcription Factor-2 / Q000235:genetics; D051757:PAX5 Transcription Factor / Q000235:genetics; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D020794:Receptor Protein-Tyrosine Kinases; D012189:Retrospective Studies; D016019:Survival Analysis; D015534:Trans-Activators / Q000235:genetics
chemical_list: D014408:Biomarkers, Tumor; D050813:Octamer Transcription Factor-2; D051757:PAX5 Transcription Factor; C497281:PAX5 protein, human; C091546:POU2AF1 protein, human; D015534:Trans-Activators; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D011505:Protein-Tyrosine Kinases; D020794:Receptor Protein-Tyrosine Kinases